C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 3.95 USD 2.73% Market Closed
Market Cap: 278.8m USD
Have any thoughts about
C4 Therapeutics Inc?
Write Note

Income Statement

Earnings Waterfall
C4 Therapeutics Inc

Revenue
33.7m USD
Operating Expenses
-150.6m USD
Operating Income
-116.9m USD
Other Expenses
11.4m USD
Net Income
-105.5m USD

Income Statement
C4 Therapeutics Inc

Rotate your device to view
Income Statement
Currency: USD
Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
34
N/A
34
+0%
46
+35%
46
+0%
50
+9%
48
-3%
31
-36%
27
-13%
16
-41%
20
+27%
21
+2%
20
-3%
29
+47%
34
+15%
Operating Income
Operating Expenses
(114)
(120)
(128)
(139)
(148)
(155)
(161)
(162)
(161)
(160)
(160)
(153)
(146)
(151)
Selling, General & Administrative
(26)
(31)
(33)
(39)
(40)
(41)
(43)
(41)
(41)
(42)
(42)
(41)
(41)
(42)
Research & Development
(88)
(89)
(95)
(100)
(108)
(114)
(118)
(121)
(119)
(118)
(118)
(111)
(105)
(109)
Operating Income
(80)
N/A
(86)
-7%
(82)
+4%
(93)
-13%
(98)
-6%
(107)
-8%
(130)
-22%
(134)
-4%
(145)
-8%
(140)
+3%
(139)
+1%
(133)
+5%
(116)
+12%
(117)
0%
Pre-Tax Income
Interest Income Expense
(7)
(4)
(2)
(2)
(1)
(0)
1
3
5
7
8
11
13
14
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
(1)
(1)
(3)
(3)
(2)
Pre-Tax Income
(87)
N/A
(90)
-3%
(84)
+7%
(95)
-13%
(99)
-5%
(107)
-7%
(128)
-20%
(131)
-2%
(140)
-6%
(134)
+4%
(131)
+2%
(125)
+5%
(107)
+15%
(105)
+1%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
0
(1)
(1)
0
0
(0)
Income from Continuing Operations
(87)
(90)
(84)
(95)
(99)
(107)
(128)
(131)
(140)
(135)
(132)
(126)
(108)
(105)
Net Income (Common)
(82)
N/A
(80)
+3%
(84)
-5%
(95)
-13%
(99)
-5%
(107)
-7%
(128)
-20%
(131)
-2%
(140)
-6%
(135)
+4%
(132)
+2%
(126)
+5%
(108)
+14%
(105)
+2%
EPS (Diluted)
-1.87
N/A
-1.64
+12%
-1.82
-11%
-1.94
-7%
-2.04
-5%
-2.18
-7%
-2.62
-20%
-2.68
-2%
-2.85
-6%
-2.75
+4%
-2.67
+3%
-1.84
+31%
-1.56
+15%
-1.51
+3%

See Also

Discover More